CorMedix (CRMD) Cash & Equivalents (2010 - 2026)

CorMedix has reported Cash & Equivalents for 16 years, with the latest figure at $144.8 million in Q4 2025.

• Quarterly Cash & Equivalents rose 256.29% year-over-year to $144.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $144.8 million (up 256.29% YoY) and the FY2025 annual result came in at $144.8 million, up 256.29% from the prior year.
• Cash & Equivalents grew to $144.8 million in Q4 2025 per CRMD's latest filing, from $48.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $159.3 million in Q2 2025 and troughed at $19.7 million in Q2 2023.
• A 5-year average of $52.9 million and a median of $43.2 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents soared 44315.93% in 2021, then tumbled 70.38% in 2022.
• Over 5 years, Cash & Equivalents stood at $53.3 million in 2021, then fell by 19.07% to $43.1 million in 2022, then grew by 1.15% to $43.6 million in 2023, then slipped by 6.85% to $40.7 million in 2024, then jumped by 256.29% to $144.8 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $144.8 million, $48.5 million, and $159.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.